# 18F-Fluciclovine PET/CT in Multiple Myeloma

> **NCT06103838** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma
- Newly Diagnosed Multiple Myeloma (NDMM)
- Relapsed and/or Refractory Multiple Myeloma (RRMM)

## Interventions

- **DRUG:** 18F-fluciclovine injection
- **PROCEDURE:** 18F-FDG PET/CT

## Key facts

- **NCT ID:** NCT06103838
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2026-12-06
- **Final completion:** 2031-12-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06103838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06103838, "18F-Fluciclovine PET/CT in Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06103838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*